HHGC
HZNP

Hunting Hill Global Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Hunting Hill Global Capital’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-300,400
Closed -$34.8M – 159
2023
Q3 		$34.8M Sell
300,400
-6,300
-2% -$677K 11.58% 3
2023
Q2 		$31.5M Buy
306,700
+204,000
+199% +$21.5M 10.11% 3
2023
Q1 		$11.2M Buy
+102,700
New +$11.4M 8.79% 4

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Hunting Hill Global Capital's HZNP Position: Q4 2023 in Review

Hunting Hill Global Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 219,982 shares — an estimated $25.4M sold.

Hunting Hill Global Capital first reported a position in HZNP in Q1 2023 and held it in 3 quarters. The position peaked at $25.7M in Q2 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Hunting Hill Global Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Hunting Hill Global Capital sold 219,982 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $25.4M.
  • Hunting Hill Global Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023 and held it in 3 quarters.
  • Hunting Hill Global Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $25.7M in Q2 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Hunting Hill Global Capital's 13F filing for Q4 2023, filed 14 Feb 2024.